Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Purchased by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S grew its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 271.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 62,908 shares of the medical equipment provider’s stock after acquiring an additional 45,973 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Lantheus were worth $3,900,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Tucker Asset Management LLC increased its holdings in Lantheus by 239.0% during the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 282 shares during the last quarter. Principal Securities Inc. acquired a new stake in shares of Lantheus during the fourth quarter worth approximately $28,000. Covestor Ltd increased its stake in shares of Lantheus by 62.7% in the third quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 203 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in Lantheus by 36.6% in the third quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock valued at $40,000 after acquiring an additional 156 shares in the last quarter. Finally, NBC Securities Inc. bought a new position in Lantheus during the 3rd quarter valued at $46,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of Lantheus stock in a transaction on Wednesday, March 6th. The stock was purchased at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the purchase, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were purchased at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the purchase, the insider now directly owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the transaction, the director now owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. Insiders have sold a total of 94,545 shares of company stock valued at $6,177,295 in the last quarter. Company insiders own 2.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. JMP Securities restated a “market outperform” rating and set a $100.00 price objective on shares of Lantheus in a research note on Friday, February 23rd. Truist Financial lifted their target price on Lantheus from $82.00 to $96.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. B. Riley boosted their price target on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a report on Thursday, April 18th. Finally, Mizuho raised their price objective on Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and an average price target of $99.17.

Lantheus Stock Performance

Shares of Lantheus stock traded up $1.35 on Monday, reaching $81.02. 160,589 shares of the company were exchanged, compared to its average volume of 1,050,362. The firm has a market cap of $5.62 billion, a price-to-earnings ratio of 12.16 and a beta of 0.52. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $100.48. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.55 and a current ratio of 4.84. The company’s 50-day moving average is $65.20 and its two-hundred day moving average is $63.47.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. The firm had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. As a group, research analysts expect that Lantheus Holdings, Inc. will post 5.96 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.